Glaukos Co. (NYSE:GKOS) Receives Consensus Recommendation of “Hold” from Brokerages

Glaukos Co. (NYSE:GKOS) has received an average recommendation of “Hold” from the ten brokerages that are covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation and seven have issued a hold recommendation on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $59.00.

Several analysts recently commented on GKOS shares. William Blair downgraded shares of Glaukos from an “outperform” rating to a “market perform” rating and set a $34.00 price target for the company. in a research report on Wednesday, July 14th. Oppenheimer downgraded shares of Glaukos from an “outperform” rating to a “market perform” rating and set a $105.00 price objective for the company. in a research report on Wednesday, July 14th. Wells Fargo & Company downgraded shares of Glaukos from an “equal weight” rating to an “underweight” rating and set a $41.00 price objective for the company. in a research report on Tuesday, July 20th. TheStreet downgraded shares of Glaukos from a “c-” rating to a “d+” rating in a research report on Wednesday, May 26th. Finally, Citigroup cut their price objective on shares of Glaukos from $94.00 to $52.00 and set a “neutral” rating for the company in a research report on Wednesday, July 28th.

Shares of Glaukos stock traded up $0.10 during trading hours on Friday, hitting $52.93. The company had a trading volume of 3,596 shares, compared to its average volume of 488,094. The company’s 50-day moving average is $53.84 and its two-hundred day moving average is $73.01. Glaukos has a twelve month low of $43.66 and a twelve month high of $99.00. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.40 and a quick ratio of 1.35. The company has a market cap of $2.46 billion, a P/E ratio of -40.25 and a beta of 1.67.

Glaukos (NYSE:GKOS) last released its quarterly earnings results on Thursday, August 5th. The medical instruments supplier reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.13. Glaukos had a negative net margin of 21.24% and a negative return on equity of 3.13%. The firm had revenue of $78.09 million during the quarter, compared to the consensus estimate of $71.00 million. Sell-side analysts expect that Glaukos will post -0.85 EPS for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in GKOS. Baillie Gifford & Co. increased its holdings in shares of Glaukos by 22.9% in the 1st quarter. Baillie Gifford & Co. now owns 5,977,576 shares of the medical instruments supplier’s stock valued at $501,698,000 after purchasing an additional 1,113,052 shares in the last quarter. Macquarie Group Ltd. grew its stake in Glaukos by 94,784.7% in the 2nd quarter. Macquarie Group Ltd. now owns 1,105,407 shares of the medical instruments supplier’s stock valued at $93,772,000 after acquiring an additional 1,104,242 shares during the last quarter. BlackRock Inc. grew its stake in Glaukos by 4.0% in the 1st quarter. BlackRock Inc. now owns 7,270,447 shares of the medical instruments supplier’s stock valued at $610,209,000 after acquiring an additional 282,548 shares during the last quarter. Fred Alger Management LLC grew its stake in Glaukos by 56.1% in the 1st quarter. Fred Alger Management LLC now owns 699,929 shares of the medical instruments supplier’s stock valued at $58,745,000 after acquiring an additional 251,678 shares during the last quarter. Finally, Dimensional Fund Advisors LP acquired a new stake in Glaukos in the 2nd quarter valued at about $18,778,000.

Glaukos Company Profile

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B.

See Also: What are the components of an earnings report?

Analyst Recommendations for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.